文献速递糖尿病

非奈利酮对1型糖尿病合并CKD患者白蛋白尿的疗效:按基线HbA1c和糖尿病病程的探索性分析

Effect of Finerenone on Albuminuria in Type 1 Diabetes by Baseline HbA1c Level and Diabetes Duration: An Exploratory Analysis of the FINE-ONE Trial.
PubMed 文献 · Diabetes Care · 2026-01-01

FINE-ONE试验的探索性分析纳入242例1型糖尿病合并慢性肾脏病成人患者,按基线HbA1c和糖尿病病程分层,评估非奈利酮对尿白蛋白/肌酐比值(UACR)的影响。结果显示,6个月时非奈利酮组UACR较安慰剂组校正后降低25%(95%CI -35%至-13%,P=0.0001),且疗效在不同HbA1c三分位和糖尿病病程三分位间一致(交互P分别为0.41和0.70)。总体安全性和高钾血症发生率在各HbA1c三分位间相似。

要点

  • 非奈利酮在1型糖尿病合并CKD患者中6个月降低UACR达25%(安慰剂校正)。
  • 疗效不受基线HbA1c水平或糖尿病病程影响,交互作用无统计学意义。
  • 不同HbA1c三分位间总体安全性和高钾血症发生率相似。

核心结论

  • 在1型糖尿病合并CKD成人中,非奈利酮降低UACR且耐受性良好,不受基线HbA1c水平或糖尿病病程影响。

研究设计与样本

  • FINE-ONE试验的探索性分析,纳入242例1型糖尿病合并CKD成人患者,随机分配至非奈利酮或安慰剂组。

主要发现

  • 6个月时非奈利酮组UACR中位数从574.6降至373.5 mg/g,安慰剂组从506.4降至475.6 mg/g,安慰剂校正后变化为-25%(95%CI -35%至-13%,P=0.0001)。
  • 按基线HbA1c三分位(<7.1%、≥7.1%至≤8.1%、>8.1%)分层,安慰剂校正后UACR变化分别为-17%(95%CI -40%至13%)、-18%(95%CI -39%至10%)和-37%(95%CI -55%至-13%),交互P=0.41。
  • 按糖尿病病程三分位分层,疗效一致(交互P=0.70)。
  • 6个月时HbA1c组间差异为+0.04%(95%CI -0.17%至0.24%,P=0.74)。
  • 总体安全性和高钾血症发生率在各HbA1c三分位间相似。

临床怎么用

  • 对于1型糖尿病合并CKD患者,无论血糖控制水平或糖尿病病程,非奈利酮均可考虑用于降低白蛋白尿。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate whether the efficacy and safety of finerenone varied by baseline hemoglobin A1c (HbA1c) level, a proxy of glycemic control, and diabetes duration in people with type 1 diabetes and chronic kidney disease (CKD). RESEARCH DESIGN AND METHODS: Adults with type 1 diabetes, urinary albumin-to-creatinine ratio (UACR) 200 to <5,000 mg/g, and estimated glomerular filtration rate (eGFR) 25 to <90 mL/min/1.73 m2 were randomly assigned (one to one) to finerenone or placebo. UACR change from baseline over 6 months by baseline HbA1c and diabetes duration was analyzed. RESULTS: Baseline HbA1c was available for 240 of 242 participants; mean (SD) HbA1c, diabetes duration, and eGFR were 7.6% (1.1%; 60 [12] mmol/mol), 32.0 (14.2) years, and 58.9 (19.2) mL/min/1.73 m2, respectively. At 6 months, HbA1c (95% CI) remained unchanged (finerenone +0.03% [-0.14%, 0.20%]; placebo 0.00% [-0.12%, 0.11%]; between-group difference +0.04% [-0.17%, 0.24%]; P = 0.74). Over 6 months, median UACR decreased from 574.6 to 373.5 mg/g with finerenone and from 506.4 to 475.6 mg/g with placebo, corresponding to a -25% placebo-corrected change (95% CI -35%, -13%; P = 0.0001). Treatment effects were consistent across HbA1c tertiles (<7.1%, ≥7.1% to ≤8.1%, and >8.1%), with placebo-corrected UACR changes (95% CIs) of -17% (-40%, 13%), -18% (-39%, 10%), and -37% (-55%, -13%), respectively (P interaction = 0.41). Effects were similarly consistent across diabetes duration tertiles (P interaction = 0.70). Overall safety and incidence of hyperkalemia were similar across HbA1c tertiles. CONCLUSIONS: In adults with type 1 diabetes and CKD, finerenone reduced UACR and was well tolerated irrespective of HbA1c level or diabetes duration.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Beernink JM, Heerspink HJL, Birkenfeld AL, et al. Effect of Finerenone on Albuminuria in Type 1 Diabetes by Baseline HbA1c Level and Diabetes Duration: An Exploratory Analysis of the FINE-ONE Trial. Diabetes Care. 2026. PMID: 42258447. doi:10.2337/dc26-0882

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。